A Phase I Safety Study of NVG-291 in Healthy Adults
← catalyst calendarSponsored by NervGen Pharma (industry) · NGEN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
74actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-02
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-06 | actual | When the study began enrolling |
| Primary completion | 2023-06-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2023-07-03 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-01-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Spinal Cord Injury
Interventions
- Drug: NVG-291
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAdverse Events
measured Assessed through 7 days following the last dose of study drug
Related
NGEN's other studiesmost recently updated first
- A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury Phase 3 · Not yet recruiting
- NVG-291 in Spinal Cord Injury Subjects Phase 1/2 · Completed
Permalink · NGEN's whole pipeline · Catalyst calendar · Every registered study · What changed